Dernières nouvelles pour TIM (NYSE:TIMB) Stock

TIM, which is 67%-owned by Telecom Italia, is the third largest wireless carrier in Brazil, with 62 million subscribers, equal to about 24% of the market. The firm also owns 49% of I-Systems, an infrastructure partnership that is expanding its network footprint across Brazil. I-Systems can provide broadband service to about 9 million locations, equal to 10%-15% of the country. TIM leases capacity on the venture's network to serve retail broadband customers under the UltraFibra brand. TIM also resells fiber network access from other providers, including Oi's former infrastructure business V.tal. In total, TIM claims it can offer fixed broadband service to about 16 million locations.

TIM S.A. American Depositary Shares (Each representing 5 Common Shares)

TIM SA

Timber Pharmaceuticals Inc COM NEW

Timber Pharmaceuticals Inc Ordinary Shares

TIMBERCREEK FNCL CORP by Timbercreek Financial Corp.

Timbercreek Financial Corp

Timberland Bancorp Inc

Timberline Resources Corp

In the current session, the stock is trading at $76.47, after a 0.05% increase. Over the past month, Sempra Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SRE#NYSE">SRE</a>) stock increased by 0.92%, and in the past year, by 1.51%. With performance like this, long-term shareholders are optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.

<img src="https://www.benzinga.com/files/images/story/2025/1749146420_0.png" alt="Past Year Chart" />

<h3>How Does Sempra P/E Compare to Other Companies?</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Compared to the aggregate P/E ratio of the 19.23 in the Multi-Utilities industry, Sempra Inc. has a lower P/E ratio of 16.8. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1749146420_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

News

Intraday Update

Markets

Price Over Earnings Overview: Sempra

Palantir Technologies Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) CEO Alex Karp denied claims on Thursday suggesting the company is aiding the government <a href="https://www.benzinga.com/markets/tech/25/06/45764231/palantir-says-it-doesnt-unlawfully-spy-on-americans-calls-report-alleging-use-by-trump-administration-for-surveillance-blatantly-untrue">in unlawful surveillance</a>.
What Happened: The New York Times <a href="https://www.nytimes.com/2025/05/30/technology/trump-palantir-data-americans.html">reported</a> last week that the Trump Administration has tapped Palantir to collect data on Americans after President Donald Trump signed an executive order in March calling on the federal government to enable the sharing of data across agencies. 
Thursday on CNBC&#8217;s &#8220;Squawk On The Street,&#8221; Karp refuted the report. 
&#8220;The Palantir platform, despite what you might read at The New York Times, is actually the most secure, the hardest platform in the world to manipulate and change &#8230; If you wanted to use the Deep State to unlawfully surveil people, the last platform in the world you would pick is Palantir,&#8221; Karp said. 
Palantir recently secured new <a href="https://www.benzinga.com/news/contracts/25/05/45702431/palantir-stock-gains-as-trump-expands-companys-role-in-us-government-agencies">contracts</a> with the Department of Homeland Security and the Pentagon. The New York Times report indicates that Palantir representatives are also in talks with the Social Security Administration and the Internal Revenue Service, and argues that wide government adoption of a single platform creates an easy path for Trump to combine data from different agencies.
Karp told CNBC that the article is &#8220;ridiculous&#8221; and shows that the publication doesn&#8217;t have proper technical knowledge. He noted that a random engineer could find 15 to 20 errors in the article in 90 seconds. 
If you spent 10 minutes looking at the architecture of the Palantir platform, you would see how ridiculous the report is, he said.
&#8220;By the way, writing ridiculous sh&#x2A;&#x2A; in a highly-charged environment is dangerous, and The New York Times should take responsibility for the dangers they&#8217;re putting out in the world. There really are people that believe that crap,&#8221; the Palantir CEO said. 
The New York Times report shows that Palantir is winning, he said, adding that U.S. government revenue is up 46% and U.S. commercial revenue is up 71%. He told CNBC that the company is seeing strong growth because the product is the best in the world. The Trump administration is buying the best, most secure product available, that&#8217;s cheaper and more efficient, and replacing older systems, he said. 
&#8220;You know what we&#8217;re doing in the DOD, we&#8217;re scaring the bejeebers — I&#8217;m trying not to use the F word — out of our adversaries by making them scared at night &#8230; installing productized software that runs algorithms against data that&#8217;s been lawfully collected. And you can&#8217;t unlawfully use it in our platform, which is one of the main reasons people buy it and keep it,&#8221; Karp said. 
Palantir said in its <a href="https://www.benzinga.com/news/earnings/25/05/45208000/palantir-q1-earnings-revenue-beat-eps-in-line-customer-count-up-39-company-raises-guidance-citing-surging-and-ferocious-growth">earnings report</a> last month that the company&#8217;s customer count grew 39% year-over-year and 8% on a quarter-over-quarter basis. Palantir raised its guidance for full-year U.S. commercial revenue, adjusted income from operations and adjusted free cash flow.&nbsp;
PLTR Price Action: <a href="https://www.benzinga.com/quote/PLTR" target="_blank" rel="noreferrer noopener">Palantir shares</a> are up approximately 64% year-to-date. The stock was down 5.58% at $122.67 at the time of publication Thursday, according to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/25/06/45784629/cathie-wood-dumps-another-5-2-million-of-palantir-stock-amid-trump-administration-linked-surveillance-controversy">Cathie Wood Dumps Another $5.2 Million Of Palantir Stock Amid Trump Administration-Linked Surveillance Controversy</a></li>
</ul>
Photo: Sundry Photography/Shutterstock.

Government

Tech

PLTR

Palantir CEO Alex Karp Refutes 'Ridiculous' Surveillance Reports, Says Company Is 'Winning'

Alvotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALVO#NASDAQ">ALVO</a>) on Thursday collaborated with Dr. Reddy's Laboratories Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDY#NYSE">RDY</a>) to co-develop, manufacture and commercialize a biosimilar candidate to Keytruda (pembrolizumab) <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/b45788813/alvotech-and-dr-reddys-enter-into-collaboration-to-co-develop-biosimilar-candidate-to-keytruda-pem" rel="noreferrer noopener">for global markets</a>.
Merck &amp; Co Inc's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) Keytruda (pembrolizumab) is indicated for numerous cancer types.
Keytruda's worldwide sales were $29.5 billion in 2024. The collaboration combines Dr. Reddy's and Alvotech's capabilities in biosimilars, speeding up the development process and extending the global reach for this biosimilar candidate.
Under the terms of the agreement, the parties will be jointly responsible for developing and manufacturing the biosimilar candidate and sharing costs and responsibilities.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44724763/pharma-industry-faces-jitters-as-trump-hints-at-historic-tariffs-bofa-outlines-probable-timeline" rel="noreferrer noopener">Pharma Industry Faces Jitters As Trump Hints At Historic Tariffs, BofA Outlines Probable Timeline</a>
Subject to certain exceptions, each party will have the right to commercialize the product globally.
In May, the U.S. Food and Drug Administration (FDA) approved&nbsp;Teva and&nbsp;Alvotech Selarsdi (ustekinumab-aekn) injection as interchangeable with the reference biologic&nbsp;Johnson &amp; Johnson's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) <a target="_blank" href="https://www.benzinga.com/general/biotech/25/05/45199025/why-is-israel-based-generic-drug-focused-teva-pharmaceutical-stock-trading-higher-on-monday" rel="noreferrer noopener">Stelara (ustekinumab)</a>.
In March, Alvotech&nbsp;announced the acquisition of&nbsp;R&amp;D operations of&nbsp;Xbrane Biopharma AB along with a biosimilar candidate, XB003, which is based on Cimzia (certolizumab pegol)&nbsp;for <a target="_blank" href="https://www.benzinga.com/news/mid-cap/25/03/44412592/alvotech-strengthens-biosimilar-portfolio-with-27-million-xbrane-rd-deal" rel="noreferrer noopener">around SEK275 million</a> (around $27 million).
The transaction includes a cash payment of SEK102.2 million at closing, along with the assumption of SEK172.8 million in debt and accounts payable.
HSBC upgraded Dr Reddy's Laboratories from Hold to Buy and raised the price <a target="_blank" href="https://www.benzinga.com/quote/RDY/analyst-ratings" rel="noreferrer noopener">forecast from $14.44 to $16.9</a>.
<h2 class="wp-block-heading">Stock Prediction For 2025 For Alvotech</h2>
Equity research analysts on and off Wall Street typically use earnings growth and fundamental research as a form of valuation and forecasting. But many in trading turn to technical analysis as a way to form predictive models for share price trajectory.
Some investors look to trends to help forecast where they believe a stock could trade at a certain point in the future. Looking at Alvotech, an investor could make an assessment about a stock's long term prospects using a moving average and trend line. If they believe a stock will remain above the moving average, which many believe is a bullish signal, they can extrapolate that trend into the future using a trend line. For Alvotech, the 200-day moving average sits at $11.44, according to <a target="_blank" href="https://pro.benzinga.com/" rel="noreferrer noopener">Benzinga Pro</a>, which is above the current price of $10.46. For more on charts and trend lines, <a target="_blank" href="https://pro.benzinga.com/" rel="noreferrer noopener">see a description here.</a>
Traders believe that when a stock is above its moving average, it is a generally bullish signal, and when it crosses below, it is a more negative signal. Investors could use trend lines to make an educated guess about where a stock could trade at a later date if conditions remain stable.
Price Action: At the last check on Thursday, RDY stock was up 6.07% at $15.65, and ALVO stock was down 2.49% at $10.56.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/biotech/25/06/45799258/gileads-hiv-pipeline-gains-traction-with-upcoming-fda-decision-for-hiv-1-drug" target="_blank" rel="noreferrer noopener">Gilead's HIV Pipeline Gains Traction With Upcoming FDA Decision For HIV-1 Drug</a></li>
</ul>
Photo by T. Schneider via Shutterstock

Health Care

Contracts

Movers

Trading Ideas

General

ALVO

Dr Reddy's And Alvotech Join Hands To Develop Biosimilar For Merck's Blockbuster Cancer Drug

If you're holding the VanEck Green Infrastructure ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNEW#NASDAQ">RNEW</a>) or VanEck HIP Sustainable Muni ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/SMI#BATS">SMI</a>) funds, it's time to check your portfolio. VanEck is pulling the plug on <a href="https://www.benzinga.com/etfs">both products</a> later this month.
The deadline to trade these ETFs on the stock market is June 18. From there on, they&#8217;ll be delisted, and the remaining shareholders will be paid in cash around June 25, according to the net asset value of their investments.
Also Read: <a href="https://www.benzinga.com/etfs/sector-etfs/25/06/45796685/nvidia-beats-microsoft-to-be-the-biggest-of-the-big-here-are-6-etfs-riding-its-trillion-dollar-rebound">Nvidia Beats Microsoft To Be The Biggest Of The Big: Here Are 6 ETFs Riding Its Trillion-Dollar Rebound</a>
<h2 class="wp-block-heading">Why Is VanEck Doing This?</h2>
In short: low performance and low demand. VanEck takes a regular look at its fund lineup to determine what&#8217;s hot and what&#8217;s not. These two sustainable-themed ETFs lacked sufficient assets or investor interest to remain in play.
The firm wasn&#8217;t specific, but it&#8217;s a common scenario— if a fund isn&#8217;t growing or gaining traction, even such large players as VanEck won&#8217;t retain it indefinitely.
<h2 class="wp-block-heading">What This Means For You</h2>
If you hold RNEW or SMI shares, you can trade them on your online brokerage site up to and including June 18 (your brokerage fees may apply). If you do not sell before then, you will be automatically paid out in cash on approximately June 25, the value of the fund at the time of liquidation.
You could also see a final income or capital gains distribution when the fund is closed.
For tax purposes, the liquidation will be treated as a capital gain or loss based on your cost basis. VanEck will distribute year-end tax information.
This action follows a broader trend in the ETF space. Asset managers are consolidating their product offerings, particularly when niche or thematic ETFs don&#8217;t attract sufficient investor capital. ESG investing isn&#8217;t disappearing, but it&#8217;s clear that not all &#8220;green&#8221; funds are meant to be permanent.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/etfs/sector-etfs/25/06/45779722/global-x-debuts-covered-call-bitcoin-etf-aims-to-keep-volatility-in-check">Global X Debuts Covered Call Bitcoin ETF, Aims To Keep Volatility In Check</a></li>
</ul>
Photo: Shutterstock

New ETFs

ETFs

RNEW

Semiconductor Manufacturing International

VanEck Shutters ESG ETFs RNEW, SMI Amid Low Demand For Green Investment Funds

Monness, Crespi, Hardt analyst Brian White upgrades MongoDB (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDB#NASDAQ">MDB</a>) from Neutral to Buy and announces $295 price target.

Upgrades

Price Target

Analyst Ratings

Monness, Crespi, Hardt Upgrades MongoDB to Buy, Announces $295 Price Target

WIIM

Hamilton Insurance Group shares are trading lower after BMO Capital downgraded the stock from Outperform to Market Perform.

Oshkosh shares are trading higher after the company shared its strategy for growth and 2028 financial targets.

AMC Entertainment Holdings Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMC#NYSE">AMC</a>) on Tuesday <a target="_blank" href="https://www.benzinga.com/topic/amc" rel="noreferrer noopener">reached an agreement</a> with&nbsp;National CineMedia Inc to run more advertising in its theaters.
From July 1, AMC theater screens will feature a "platinum spot" before the start of a film, Bloomberg <a target="_blank" href="https://www.bloomberg.com/news/articles/2025-06-03/amc-theaters-to-run-even-more-commercials-before-movies-play?srnd=phx-technology&amp;sref=TBDibEcD" rel="noreferrer noopener">reported</a> on Thursday. The theater chain will get a cut of the ad sales.
National CineMedia owns and operates an ad network in major theater chains, including AMC,&nbsp;Cinemark Holdings Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNK#NYSE">CNK</a>), and Regal Cinemas.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/25/05/45385919/amc-stock-rises-as-theater-chain-launches-50-off-wednesdays" rel="noreferrer noopener">AMC Stock Rises As Theater Chain Launches 50% Off Wednesdays</a>
AMC reported <a target="_blank" href="https://www.benzinga.com/general/entertainment/25/05/45268260/amc-q1-earnings-highlights-double-beat-ceo-highlights-2025-2026-slate-as-box-office-doubles-in-april" rel="noreferrer noopener">first-quarter revenue</a> of $862.5 million, down 9.3% year-over-year. The total beat a Street consensus estimate of $837.1 million<a target="_blank" href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0507" rel="noreferrer noopener">.</a>
The company reported an adjusted loss of 58 cents per share for the quarter, beating a Street consensus estimate of 59 cents per share.
Total attendance was 41.9 million in the first quarter, down 10.1%. U.S. attendance was 26.9 million, down 11.8%, while international attendance of 15.0 million was down 7.1%.
AMC's CEO,&nbsp;Adam Aron, <a target="_blank" href="https://www.benzinga.com/25/05/45276888/amc-ceo-says-q1-was-the-worst-domestic-box-office-since-covid-19but-expects-a-rebound-in-2025-with-barn-burners-coming-all-year" rel="noreferrer noopener">remains upbeat and has</a> a strong outlook for the rest of this year, pointing to a packed slate of major studio releases for the summer and beyond.
AMC expects the 2025 domestic box office to land at the upper end of its prior forecast, potentially $500 million to $1 billion higher than last year.
AMC <a target="_blank" href="https://www.benzinga.com/25/05/45616728/amc-entertainment-stock-is-rising-tuesday-whats-going-on" rel="noreferrer noopener">announced that the</a> Memorial Day holiday weekend spanning Thursday through Monday was the company's third-biggest revenue total for a five-day period in over 10 years, driven by robust openings from "Lilo &amp; Stitch," as well as "Mission: Impossible — The Final Reckoning."
More than seven million people attended AMC locations in the&nbsp;U.S. and ODEON Cinemas internationally, which helped the company record its highest attendance on Fridays, Saturdays, and Sundays of the year in the U.S.
AMC&nbsp;stock declined 34% in the last 12 months as it grappled with weak box office performance since the COVID-19 pandemic.
Price Action: AMC stock is up 1.76% at $3.46 at last check Thursday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/04/44993820/imax-gains-analyst-praise-for-strong-q1-china-growth-but-tariff-film-import-risks-loom" target="_blank" rel="noreferrer noopener">Imax Wins Analyst Praise On Strong Film Slate, But China Market Volatility Raises Concerns</a></li>
</ul>
Photo via Shutterstock

Media

AMC Eyes Ad Revenue Lift With Premium Pre-Movie Ads

<a href="https://x.com/elonmusk/status/1930682121464795484?s=46&amp;t=dtUiyC3dUs5yGRgT9qYHWg">https://x.com/elonmusk/status/1930682121464795484?s=46&amp;t=dtUiyC3dUs5yGRgT9qYHWg</a>

TSLA

Elon Musk Posts On X "The Big Ugly Bill will INCREASE the deficit to $2.5 trillion!"

Mizuho analyst David Bellinger maintains Five Below (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIVE#NASDAQ">FIVE</a>) with a Neutral and raises the price target from $100 to $115.

FIVE

Mizuho Maintains Neutral on Five Below, Raises Price Target to $115

Roth Capital analyst Boobalan Pachaiyappan initiates coverage on PolyPid (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYPD#NASDAQ">PYPD</a>) with a Buy rating and announces Price Target of $9.

Initiation

PYPD

Roth Capital Initiates Coverage On PolyPid with Buy Rating, Announces Price Target of $9

WYNN

Wynn Expands Middle East And European Presence With Mayfair Casino Ahead of UAE Resort Opening in 2027

Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) may still be iconic, but its stock is no longer invincible. Since peaking against <a href="https://www.benzinga.com/topic/magnificent-seven">the Magnificent 7</a> in late 2022, Apple's relative performance has plunged over 45%, a jaw-dropping fall that underlines how far the tech giant has lagged behind its Big Tech peers.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="592" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/05104834/Screenshot-2025-06-05-at-7.36.24-PM-1024x592.png" alt="" class="wp-image-939935" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/05104834/Screenshot-2025-06-05-at-7.36.24-PM-1024x592.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/05104834/Screenshot-2025-06-05-at-7.36.24-PM-300x174.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/05104834/Screenshot-2025-06-05-at-7.36.24-PM-768x444.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/05104834/Screenshot-2025-06-05-at-7.36.24-PM.png 1134w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Chart created using TradingView
A price ratio chart comparing Apple to the aggregate Mag 7 soared to 0.17 in November 2022. Fast forward to June 2025, and that figure has collapsed to 0.09. While the broader Mag 7 group has powered ahead on AI momentum, Apple has been on a different trajectory — down 17% year-to-date and struggling to reclaim its former leadership.
Read Also: <a href="https://www.benzinga.com/news/topics/25/06/45790909/was-jeff-bezos-backed-whylabs-secretly-acquired-by-apple-after-10m-series-a-to-compete-in-ai-arms-race-against-google-openai-and-microsoft">Was Jeff Bezos-Backed WhyLabs Secretly Acquired By Apple After $10M Series A To Compete In AI Arms Race Against Google, OpenAI, And Microsoft?</a>
<h1 class="wp-block-heading">Tariffs, Tech Turmoil &amp; iPhone Woes</h1>
The biggest culprit? Geopolitics. 
Apple's reliance on Chinese manufacturing has put it squarely in the crosshairs of Trump-era tariffs. A <a href="https://www.benzinga.com/content/45653187/apple-sinks-after-new-25-tariff-announcement-whats-the-bottom">recent 25% tariff</a> threat on non-U.S.-made iPhones shaved billions off Apple's market cap overnight, exposing the company&#8217;s supply chain vulnerabilities. While <a href="https://in.benzinga.com/markets/equities/25/05/45637672/apple-ramps-up-india-manufacturing-as-us-iphone-imports-surge-76-in-april-while-shipments-from-china-plunge">production shifts to India</a> may soften the blow, they come with time and cost.
Add to that broader market weakness — interest rate uncertainty, stretched valuations and flagging iPhone enthusiasm —and you've got a recipe for underperformance.
AAPL stock has been the worst-performing Mag 7 stock in 2025, shedding momentum as investors rotate toward names more plugged into the AI boom.
<h1 class="wp-block-heading">Is Services Growth Enough To Offset Hardware Drag?</h1>
There's still one bright spot: services. Apple's services division posted $26.3 billion in first quarter revenue with 75% margins, offering a strong buffer against hardware volatility. Analysts project this segment could reach $180 billion by 2030, helping to shift Apple's growth narrative from devices to recurring revenue.
Still, the question remains whether services growth is enough to counter declining iPhone excitement and regulatory pressures. With competitors such as Samsung, Huawei and Alphabet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) accelerating innovation, Apple's path forward will require more than just ecosystem loyalty — it'll need breakthroughs that reignite investor confidence.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/asia/25/06/45787934/apple-and-alibabas-ai-launch-in-china-delayed-by-us-china-trade-tensions-and-regulatory-hurdles-report">Apple And Alibaba&#8217;s AI Launch In China Delayed By US-China Trade Tensions And Regulatory Hurdles: Report</a></li>
</ul>
Photo: hanohiki via Shutterstock.com

Long Ideas

AAPL

GOOG

GOOGL

Apple Has Plummeted A Stunning 45% Vs. Mag 7 Since 2022

Mizuho analyst Dan Dolev upgrades Visa (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>) from Neutral to Outperform and raises the price target from $359 to $425.

Mizuho Upgrades Visa to Outperform, Raises Price Target to $425

<a href="https://www.kansascityfed.org/pdf/article/articlepage/15623/">https://www.kansascityfed.org/pdf/article/articlepage/15623/</a>

Politics

Economics

Federal Reserve

Fed's Schmid Says Expect Tariffs To Start To Show Through To Prices In Coming Months; Extent Of Tariff-driven Price Push Won't Be Fully Apparent For Some Time; Extent Of Tariffs' Drag On Growth, Employment Also Unclear

Mizuho analyst Vijay Rakesh maintains Micron Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) with a Outperform and raises the price target from $124 to $130.

Mizuho Maintains Outperform on Micron Technology, Raises Price Target to $130

Fed's Schmid Says Uncomfortable With Look-through Policy Approach To Tariff-Driven Price Increase;  Fed Policy Needs To Be 'Nimble' To Balance Two Sides Of Mandate; Focused On Maintaining Fed's Credibility On Inflation; Optimistic That Economic Activity Can Be Sustained

<ul>
<li>Board adopts cryptocurrency reserve policy as part of treasury diversification</li>
<li>Bitcoin Bourbon&#x2122; pre-launch and giveaway contest unveiled</li>
<li>FinTech veteran Matt Swann appointed to Board of Directors</li>
<li>Redefines CPG Sector to "Crypto Product Goods"</li>
</ul>
GIG HARBOR, Wash., June 05, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=pKMLg10mxKY2ZzpGLGSIBs4Fx_TK2RmTBg_hTcc5F5S-4dfdGG0OXES0zhPR1wRc1812jwZhkNqebEqqpWjt-9F-AJ0WoCEKw5eCtiE4jF4Gs0RX-2M9m-LArKr1OGXtnCNuqXWOTQK2QS9HqwiGvQ==">Heritage Distilling Holding Company, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CASK#NASDAQ">CASK</a>), North America's most awarded craft distillery, is pioneering a new category: Crypto Product Goods (CPG). This marks a shift from traditional consumer packaged goods to products built around blockchain technologies and cryptocurrency integration, making Heritage the first craft spirits company to accept crypto as a form of payment for spirits.
Cryptocurrency Treasury Reserve Policy Adopted The Company recently adopted a <a href="https://www.globenewswire.com/Tracker?data=gwhyvYTU5g9gS2t96McK5Djy6p7lIDV-PJY21nvK2EtJh1BnHAJzd5mK4eBUJgXZ_pTTBhR_N-Z7Ft6Fxw2w9w1NOA-BjjpkfMHqHCT0veDZ6pAC7EYupfhbtZp-8X0wSx4q12Vhc4Nx7z0mVG7PYbgzJHWJ1abE-ghlwfj-R3vptB1DsCrbUNxt_biDpE5OruRU90ihgYNDSDPwOwYAbPD8dMApeVn7SeinrvI3NoFmRJAqvTzdKqOE3HhnpKwj-3pbb5IkWrGLTE0Kca4a8dTpx0wP7AB87y_ffycXNYH589ptfkno5VhKbm3lQIYllDNEZ-PbKIkoFGPwkZyTyg==">Cryptocurrency Treasury Reserve Policy</a> as part of a broader strategy to diversify corporate sales and treasury operations. As a first step, the Company is preparing the pre-launch of its <a href="https://www.globenewswire.com/Tracker?data=nONPEHnrrxmuFcVPhlLpOUGe0sRvm5wVojzg-iwPlfCE1C-bb7oVM_9ocfL3Pq8qbd4AHnuClVLulNBYU4foOnTAmXMyKN73SWdUjg_NU4FtAjb6cJI0BnOidFWY8yYk">Bitcoin Bourbon</a>&#x2122;, which customers will be able to purchase using Bitcoin.
Heritage is also exploring crypto payments across its supply chain, beginning with Canadian suppliers, as it refines its blockchain protocols and infrastructure.
Looking Ahead With fewer than 125 public companies adopting crypto treasury strategies, Heritage stands out as a forward-thinking leader in both spirits and digital finance. The implementation of its cryptocurrency reserve policy marks the beginning stages of multi-stage initiative to&nbsp;ensure regulatory compliance while evolving as a crypto-enabled ecommerce brand. Company plans to unveil additional crypto-aligned products and partnerships in the months ahead.

CASK

Heritage Distilling Holding Board Adopts Cryptocurrency Reserve Policy As Part Of Treasury Diversification; Redefines CPG Sector To "Crypto Product Goods"

Morgan Stanley analyst Judah Frommer maintains Blueprint Medicines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>) with a Equal-Weight and raises the price target from $102 to $129.

BPMC

Morgan Stanley Maintains Equal-Weight on Blueprint Medicines, Raises Price Target to $129

Morgan Stanley analyst Erik Woodring reiterates Apple (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) with a Overweight and maintains $235 price target.

Reiteration

Morgan Stanley Reiterates Overweight on Apple, Maintains $235 Price Target

America Movil, S.A.B. de C.V. American Depositary Shares (each representing the right to receive twenty (20) Series B Shares

America Movil

FingerMotion

Gogo

Kore Group Holdings

PLDT

SK Telecom Co

Spok Holdings

Surgepays

Telephone and Data Systems, Inc. Common Shares

Telephone and Data Sys

Millicom International Cellular S.A. - Common Stock

Millicom Intl Cellular

Turkcell Iletisim Hizmetleri AS Common Stock

Turkcell Iletisim

T-Mobile US

uCloudlink Group Inc. - American Depositary Shares

Ucloudlink Group

United States Cellular Corporation Common Stock

United States Cellular

VEON

Vodafone Group Plc - American Depositary Shares each representing ten Ordinary Shares

Comments

TIM

Actualités

Dernières nouvelles pour TIM (NYSE:TIMB) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL